Oncologist and hematologist Ellin Berman describes how a team of experts provides a variety of therapeutic options to patients with leukemia, from standard of care treatments to new therapies available in clinical trials.
Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.
With the genomics revolution, scientists and physicians have increasingly been able to peer at the inner workings of tumor cells and pinpoint the specific genetic changes that transform them from their cells of origin into cancer.
A study led by researchers at Memorial Sloan Kettering and New York University has shown that TET2 loss enhances the function of blood stem cells, causing them to renew themselves more efficiently than normal blood stem cells.
Hematologic Oncology Division Head Marcel van den Brink comments on abstracts being presented by Memorial Sloan Kettering physicians at the 2013 American Society of Hematology Annual Meeting and Exposition.
Martin S. Tallman, MD, has been appointed Chief of the Leukemia Service in the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Cornell Medical College.
A new study led by researchers at Memorial Sloan Kettering Cancer Center (MSKCC) reports on a novel mechanism that can enhance the function of a protein that is frequently impaired in patients with acute forms of leukemia.
Scientists have uncovered new information about what orchestrates the complex balance between blood stem cells and mature blood cells, a relationship that is often disrupted in leukemia. The results will lead to a better understanding of the behavior of leukemic cells and may have vital clinical applications for patients recovering from chemotherapy, radiation therapy, or bone marrow transplantation.